A novel recombinant immuno-tBid with a furin site effectively suppresses the growth of HER2-positive osteosarcoma cells in vitro

Oncology Reports

Volumn 25, Issue 2, 2011, Pages 325-331

  Shan, Le Qun ^a   Ma, Sai ^a,b   Qiu, Xiu Chun ^a   Wang, Tao ^b   Yu, Shi Bin ^b   Ma, Bao An ^a   Zhou, Yong ^a   Fan, Qing Yu ^a   Yang, An Gang ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Bid; Gene therapy; Human epidermal growth factor receptor 2 neu; Osteosarcoma

Indexed keywords

CYTOCHROME C; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FURIN; IMMUNOTOXIN; PROTEIN BID; RECOMBINANT PROTEIN;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; BINDING SITES; BONE NEOPLASMS; CELL PROLIFERATION; DOWN-REGULATION; DRUG EVALUATION, PRECLINICAL; FURIN; HELA CELLS; HUMANS; IMMUNOCONJUGATES; OSTEOSARCOMA; PEPTIDE FRAGMENTS; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 78651347264     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2010.1074     Document Type: Article

References (38)

1. Matthey B, Engert A and Barth S: Recombinant immunotoxins for the treatment of Hodgkin's disease. Int J Mol Med 6: 509-514, 2000.
2. Schindler J, Sausville E, Messmann R, et al: The toxicity of deglycosylated ricin A chain containing immunotoxins in patients with non-Hodgkin's lymphoma is exacerbated by prior radiotherapy: a retrospective analysis of patients in five clinical trials. Clin Cancer Res 7: 255-258, 2001.
3. Kreitman RJ, Wilson WH, Bergeron K, et al: Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapyresistant hairy-cell leukemia. N Engl J Med 345: 241-247, 2001.
4. Kreitman RJ: Chimeric fusion proteins-Pseudomonas exotoxinbased. Curr Opin Investig Drugs 2: 1282-1293, 2001.
5. Henry CJ, Buss MS, Hellström I, et al: Clinical evaluation of BR96 sFv-PE40 immunotoxin therapy in canine models of spontaneously occurring invasive carcinoma. Clin Cancer Res 11: 751-755, 2005.
6. Martin PJ, Pei J, Gooley T, et al: Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation. Biol Blood Marrow Transplant 10: 552-560, 2004.
7. Wong L, Suh DY and Frankel AE: Toxin conjugate therapy of cancer. Semin Oncol 32: 591-595, 2005.
8. Chen SY, Yang AG, Chen JD, et al: Potent antitumour activity of a new class of tumour-specific killer cells. Nature 385: 78-80, 1997.
9. Von Minckwitz G, Harder S, Hövelmann S, et al: Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas. Breast Cancer Res 7: R617-R626, 2005.
10. Posey JA, Khazaeli MB, Bookman MA, et al: A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumours. Clin Cancer Res 8: 3092-3099, 2002.
11. Hall PD, Virella G, Willoughby T, et al: Antibody response to DTGM, a novel fusion toxin consisting of a truncated diphtheria toxin (DT) linked to human granulocyte-macrophage colony stimulating factor (GM), during a phase I trial of patients with relapsed or refractory acute myeloid leukemia. Clin Immunol 100: 191-197, 2001.
12. Benbrook DM: An ELISA method for detection of human antibodies to an immunotoxin. J Pharmacol Toxicol Methods 47: 169-175, 2002.
13. Onda M, Willingham M, Wang QC, et al: Inhibition of TNFalpha produced by Kupffer cells protects against the nonspecific liver toxicity of immunotoxin anti-Tac(Fv)-PE38, LMB-2. J Immunol 165: 7150-7156, 2000.
14. Baluna R and Vitetta ES: Vascular leak syndrome: a side effect of immunotherapy. Immunopharmacology 37: 117-132, 1997.
15. Erickson HA, Jund MD and Pennell CA: Cytotoxicity of human RNase-based immunotoxins requires cytosolic access and resistance to ribonuclease inhibition. Protein Eng Des Sel 19: 37-45, 2006.
16. Qiu XC, Xu YM, Wang F, et al: Single-chain antibody/activated BID chimeric protein effectively suppresses HER2-positive tumor growth. Mol Cancer Ther 7: 1890-1899, 2008.
17. Shan LQ, Qiu XC, Xu YM, et al: scFv-mediated delivery of truncated BID suppresses HER2-positive osteosarcoma growth and metastasis. Cancer Biol Ther 11: 1717-1722, 2008.
18. Wang T, Zhao J, Ren JL, et al: Recombinant immunoproapoptotic proteins with Furin site can translocate and kill HER2-positive cancer cells. Cancer Res 67: 11830-11839, 2007.
19. Jia LT, Zhang LH, Yu CJ, et al: Specific tumouricidal activity of a secreted pro-apoptotic protein consisting of HER2 antibody and constitutively active caspase-3. Cancer Res 63: 3257-3262, 2003.
20. Xu YM, Wang LF, Jia LT, et al: A caspase-6 and antihuman epidermal growth factor receptor-2 (HER2) antibody chimeric molecule suppresses the growth of HER2-overexpressing tumours. J Immunol 173: 61-67, 2004.
21. Zhao J, Zhang LH, Jia LT, et al: Secreted antibody/granzyme B fusion protein stimulates selective killing of HER2-overexpressing tumour cells. J Biol Chem 279: 21343-21348, 2004.
22. Yu CJ, Jia LT, Meng YL, et al: Selective pro-apoptotic activity of a secreted recombinant antibody/AIF fusion protein in carcinomas overexpressing HER2. Gene Ther 13: 313-320, 2006.
23. Li H, Zhu H, Xu CJ, et al: Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94: 491-501, 1998.
24. Luo X, Budlhardjo I, Zou H, et al: Bid, a Bcl-2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94: 481-490, 1998.
25. Schneider PM, Praeuer HW, Stoeltzing O, et al: Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected nonsmall cell lung cancer. Br J Cancer 83: 473-479, 2000.
26. Rasmuson T, Grankvist K and Ljungberg B: Soluble ectodomain of c-erbB-2 oncoprotein in relation to tumour stage and grade in human renal cell carcinoma. Br J Cancer 75: 1674-1677, 1997.
27. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712, 1989.
28. Menard S, Fortis S, Castiglioni F, et al: HER2 as a prognostic factor in breast cancer. Oncology 61: 67-72, 2001.
29. Gorlick R, Huvos AG, Heller G, et al: Expression of HER2/ERBB2 correlates with survival in osteosarcoma. J Clin Oncol 17: 2781-2788, 1999. (Pubitemid 29415235)
30. Onda M, Matsuda S, Higaki S, et al: ErbB2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer 77: 71-78, 1996. (Pubitemid 26002739)
31. Ferrari S, Bertoni F, Zanella L, et al: Evaluation of P-glycoprotein, HER-2/ErbB2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma. Cancer 100: 1936-1942, 2004.
32. Anninga JK, van de Vijver MJ, Cleton-Jansen AM, et al: Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas. Eur J Cancer 40: 963-970, 2004.
33. Fellenberg J, Krauthoff A, Pollandt K, et al: Evaluation of the predictive value of Her-2/neu gene expression on osteosarcoma therapy in lasermicrodissected paraffin-embedded tissue. Lab Invest 84: 113-121, 2004. (Pubitemid 41656440)
34. Zhou H, Randall RL, Brothman AR, et al: Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification. J Pediatr Hematol Oncol 25: 27-32, 2003. (Pubitemid 36070961)
35. Thomas DG, Giordano TJ, Sanders D, et al: Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma. Clin Cancer Res 8: 788-793, 2002. (Pubitemid 34742109)
36. Akatsuka T, Wada T, Kokai Y, et al: ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer 94: 1397-1404, 2002. (Pubitemid 34212632)
37. Maitra A, Wanzer D, Weinberg AG, et al: Amplification of the HER-2/neu oncogene is uncommon in pediatric osteosarcomas. Cancer 92: 677-683, 2001. (Pubitemid 32735206)
38. Chen X, Yang TT, Wang W, et al: Establishment and characterization of human osteosarcoma cell lines with different pulmonary metastatic potentials. Cytotechnology 61: 37-44, 2009.